2 Stocks That Could Soar This Year
In the volatile biotech industry, companies can see their shares soar over relatively short periods on strong clinical progress for exciting pipeline candidates.
That's precisely what could happen to (NASDAQ: EXEL) and Summit Therapeutics (NASDAQ: SMMT) this year. And the even better news is that there are reasons to consider holding onto these drugmakers' shares even beyond the next 12 months. Let's find out more.
Image source: Getty Images.
Source Fool.com
Exelixis Inc. Aktie
37,74 €
-0,59 %
Klarer Community-Favorit: Exelixis Inc. mit vielen Buy- und wenigen Sell-Einschätzungen.
Das Kursziel von 41 € für Exelixis Inc. zeigt eine leichte Steigerung gegenüber dem aktuellen Kurs von 37.74 € an.
